Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon May 06, 2024 8:12am
246 Views
Post# 36024525

RE:RE:RE:RE:RE:Spinoff of the lab worth?

RE:RE:RE:RE:RE:Spinoff of the lab worth?

Sirona Labs could be financed like ASEP did. It created a JV with a co. who contributed $7M in cash for 75% of the JV. ASEP contributed the IP for 25%. Also, the JV pays a 5% royalty to ASEP on future sales.   


PeterG wrote: Agree. The question remains open where the money is coming for the launch in Q1 2025. I'm pretty sure that Howard can't invest further Millions, the trust is gone into the company for a while. So I'm really nervous. Further dilution might come, however, the last PP has already shown less interest. I also can't see an Allergan launch in 2024 as there are no clicial trials showing on Allergans homepage for hyperpigmentation etc.!! 

 

<< Previous
Bullboard Posts
Next >>